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ABSTRACT
Aim: Spasticity is a cardinal symptom of upper motor neuron disorders. It affects different individuals differently. 
Spasticity in the hip adductor muscles can be very painful and may result in postural abnormalities and hip deformities 
that interfere with walking, transferring and perineal hygiene. The study aimed to assess the effectiveness of phenol 
obturator nerve block on hip adductor spasticity caused by the upper motor neuron lesions. 
Materials and methods: This is a single-centre retrospective study of all patients with known spasticity in the hip 
adductors who were assessed suitable for phenol nerve block of the obturator nerve. All patients had Modified 
Ashworth Scale (MAS) and the distance between the right and left femoral condyles measured in the supine position 
with the hip and knee flexed called as intercondylar distance (ICD) recorded before the procedure, 6 weeks and 24 
weeks after phenol nerve block. Nonparametric Friedman test of differences among repeated measures was 
conducted from data at 0, 6 and 24 weeks.
RESULTS: 
Obturator nerve block was performed in 52 patients using 5% aqueous phenol. The procedure was bilateral in 38 
patients and unilateral in 14 patients. There were 18 males and 34 females. There was a statistically significant 
difference between pre-injection MAS and intercondylar distance at 6 weeks and 24 weeks.
Conclusion: Phenol neurolysis of the obturator nerve helps in reducing hip adductor spasticity and helps in improving 
positioning and hygiene. With appropriate training, the procedure is simple and easy to perform without major 
complications. 
KEYWORDS: Spasticity, Phenol, Neurolysis, Obturator nerve block
INTRODUCTION:
Hip adductor spasticity is a well-known complication in 
upper motor neuron disorders including Multiple 
sclerosis, Traumatic brain injury, Spinal cord injury and 
Cerebral palsy. If hip adductor spasticity is left 
untreated, it may lead to pain, deformity, postural 
abnormality and scissoring of the hip, which can 
ultimately result in difficulty in maintaining perineal 
hygiene leading to infection and skin breakdown1,2.
 
The obturator nerve (ON) arises from ventral branches 
of second to fourth lumbar ventral rami. The nerve 
descends through the Psoas major emerging from its 
medial border at the pelvic brim to exit through the 
obturator foramen, where it divides into anterior and 
posterior branches. The anterior and posterior branches 
of ON or common ON itself run between pectineus and 
obturator externus immediately after emerging from 
obturator canal. Beyond this point, they are separated 
by part of obturator externus and lower down by 
adductor brevis. Anterior obturator nerve branch 
innervates adductor longus, adductor brevis and gracilis 
muscles and rarely pectineus. It supplies sensory 
innervation to the hip joint and a small area of skin on 
the medial thigh, but in 50% cases, it does not provide 
any cutaneous innervation3. Posterior obturator nerve 
supplies multiple motor branches to adductor magnus 
and adductor brevis, occasionally obturator externus 
O R I G I N A L  A R T I C L E
3 0P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 5  ( 4 )  O C T O B E R - D E C E M B E R  2 0 2 0
Sana Younus1, Aisha S Chachar2, Ayesha I Mian3 
and adductor longus. Posterior obturator branch gives 
sensory supply to the knee joint. The accessory 
obturator nerve is occasionally present (10%) which 
may give branches to supply pectineus, hip joint or may 
connect with anterior branch of obturator nerve3. The 
basic knowledge of the anatomy of the obturator nerve 
and its variable distribution to muscles and skin is 
important before performing any procedure to block it. 
Botulinum toxin injections (BoNT-A) are in fashion due 
to easy technique, fewer side effects, reversibility and 
more evidence in literature. Phenol used to be in 
clinical practice in the twentieth century but was 
gradually replaced by the use of BoNT-A. Phenol acts 
locally by denaturing proteins and by causing an 
anaesthetic effect. Phenol can be prepared in aqueous 
solutions or in glycerin. It causes both wallerian 
degeneration and axonal demyelination, leading to 
muscle denervation. It can also damage 
microcirculation around nerves, leading to occlusion of 
small blood vessels and fibrosis4. At different 
concentrations, it shows different actions. At 0.2% 
concentration, it is bacteriostatic and at 1%, it is 
bactericidal5. Between 1% to 7 % concentrations, it 
causes indiscriminate damage to efferent and afferent 
nerve fibers. At less than 1%, it has a local anaesthetic 
effect, which is completely reversible. The duration of 
the effective blockade after phenol injection is highly 
variable depending upon the concentration of phenol, 
total amount used, mode of application, method of 
injection and expertise of the clinician6. The most 
common side effects are post-injection burning or 
stinging sensation, dysesthesia, excessive motor 
weakness. 
There is a need to revisit the use of phenol in clinical 
practice either alone or in combination with BoNT-A 
injections or where BoNT-A can’t be used due to 
contraindications. We, therefore, conducted a 
retrospective study of all patients who underwent 
obturator nerve block with phenol at our institution 
between 2016 and August 2018 to determine whether 
phenol obturator nerve block is effective in producing 
and maintaining its effect in reducing spasticity.
MATERIALS AND METHODS:
Sample and Measure
This is a retrospective audit of all patients who 
underwent obturator nerve block with phenol during 
2016 to Aug 2018 in the regional spasticity clinic. All 
the patients were assessed by a consultant in 
rehabilitation medicine in the spasticity clinic before a 
decision was made to inject phenol. There were several 
goals of the obturator nerve block recorded in every 
patient and the most common were ease of care, ability 
to tolerate a T-roll in between the legs and improved 
posture in the bed and in the wheelchair.  
Inclusion Criteria 
All patients who presented to the spasticity clinic with 
known spasticity in the lower limbs were included in the 
study. 
EXCLUSION CRITERIA
All patients who had clinical evidence of soft-tissue 
contractures of the hip adductors were excluded from 
the study. Similarly, patients with a history of dystonic 
posture, deep vein thrombosis in the lower limbs or a 
history of adverse reaction to the phenol were not 
considered for phenol nerve block. 
INJECTION TECHNIQUE
All the patients attended the injection clinic where they 
were consented on the day of the procedure by the 
consultant in rehabilitation medicine. Patients who 
were on warfarin were advised to stop the warfarin 
three days before the procedure, and the International 
Normalized Ration (INR) was checked on the day. 
Injections were performed only if the INR was less than 
three on the day. After the injections, patients were 
advised to restart their warfarin. The procedures were 
performed by either the consultant in rehabilitation 
medicine or by the specialist registrar in rehabilitation 
medicine under the consultant’s direct supervision. 
Patients were placed supine on the plinth with the 
knees flexed at 90 degrees. An assistant helped to 
abduct the hips to facilitate access into the groin. Pubic 
tubercle was palpated with a finger and skin was 
marked with a marker about a finger breadth (1-2 cm) 
down and lateral to the pubic tubercle. This was the 
starting point to locate the nerve with a nerve 
stimulator. Once the nerve was located with a 
stimulator (a visible contraction of the hip adductors), 
the skin was marked again as an entry point for the 
needle. The antiseptic solution was used to prepare the 
skin, and 1% lidocaine (0.5 ml) was injected at the site 
of needle entry. We used a 22 G (80mm length) 
insulated nerve block needle for the procedure. The 
needle was inserted at 45 degrees and advanced while 
stimulating the nerve using a pajunk multistim SENSOR 
stimulator (I mA current and 2Hz frequency). The lowest 
current that produced a distal motor response was 
identified, and 2 ml of 5% phenol was injected. The 
nerve was stimulated again, and if there was still a 
distal motor response another 1 ml of 5% injected. This 
was continued until there was no further distal motor 
response with increasing the current. The needle was 
withdrawn, and the entry point covered with a small 
plaster. All the patients were discharged after the 
procedure. Physiotherapy assessment was completed 
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before the procedure, and a post-injection 
stretching/positioning programme was in place after the 
injection. 
FOLLOW UP 
Post-procedure follow-up in the spasticity clinic was 
arranged at 6 and 24 weeks. The follow-up visits 
included measurement of the MAS of the hip adductors 
and ICD. Any side effects were also recorded at the 
follow-up visits. 
STATISTICAL ANALYSIS 
All statistical analyses were performed using the SPSS 
24.0 (IBM SPSS, Chicago, IL, USA). Descriptive 
statistics were used to summarise the demographic 
data.  Shapiro-Wilk test was used to confirm the 
normality of the data. As the data were skewed, the 
Friedman test (non-parametric) was used to measure 
the difference between repeated measures of MAS of 
the hip adductors and intercondylar distance. The level 
of statistical significance was set at p<0.05. 
RESULTS:
Fifty-two patients with spasticity were given an 
obturator nerve block using 5% aqueous 
phenol(n=52). There were 34 (65%) females and 18 
(35%) males. Age range was 18-78 years with a mean 
age of 50.6 years The procedure was bilateral in 38 
(73%) patients and unilateral in 14 (27%) patients. 
Hence a total of 90 obturator nerves blocked were 
performed in the study.  Majority of patients (15 
patients, 28.8%, 14 females and 1 male) had the 
diagnosis of multiple sclerosis.  The diagnostic groups 
are shown in Table 1.
There was a statistically significant difference between 
pre-injection MAS and intercondylar distance at 6 
weeks and 24 weeks. The median MAS before the 
obturator nerve block was 3 which dropped to 1+ at six 
weeks follow up and to 1 at 24 weeks follow up 
appointment. There was a statistically significant 
difference between MAS before the obturator nerve 
block and at 6- and 24-weeks’ interval 
(chi-square=86.6 and p=<0.00). The mean ICD 
before the obturator nerve block was 8.88 cm which 
increased to 22.98 cm at 6 weeks and to 30.46 at 24 
weeks follow up (Figure 1). There was a statistically 
significant difference between the ICD before the 
obturator nerve block and at 6- and 24-weeks’ interval 
(chi-square=74.7 and p=<0.00). 
The duration of effects of the phenol, in our study, was 
maintained with 43 (82.6%) of patients demonstrated 
reduced spasticity at 6 months follow-up. The 
side-effects noted in our study group were minor and 
transient. Only 2 (3.8%) patients developed some 
minor bruising and pain around the injection site which 
resolved spontaneously within 48 hours. There was no 
incidence of neuropathic pain in our study. 
DISCUSSION: 
In the present study, we provided a description of 
phenol neurolysis of obturator nerve and its outcomes 
in reducing hip adductor spasticity in 90 nerves of 52 
patients with various clinical disorders. We found a 
significant reduction in MAS score of hip adductors and 
increase in ICD after this procedure. The limitation of 
this study was that it was a retrospective analysis and 
follow up period was up to 24 weeks only, but on the 
other hand, the plus points were that the procedure 
was carried out in a single institution by the same 
clinician with clinical experience in the same field for 
more than fifteen years. Hence the bias of clinical 
expertise and variability in technique was minimized. In 
our experience, obturator nerve block with phenol is 
useful in reducing adductor spasticity in advanced 
multiple sclerosis, stroke, brain injuries, prolonged 
disorder of consciousness, cerebral palsy and other 
upper motor neuron disorders. The obturator nerve 
block using phenol is a clean procedure, which can be 
performed in an outpatient setting or inpatient facility.
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There are promising results in recent past highlighting 
the importance of this less common procedure in 
achieving a reduction of spasticity without significant 
side effects7,8. Obturator nerve block involving one of 
the branches or the common trunk is effective in 
reducing adductor spasticity. The choice of nerve 
depends upon the accessibility of the nerve, which can 
be impaired secondary to spastic posturing and 
expertise of the clinician performing the procedure. We 
performed the block of the common obturator nerve. 
However, selective anterior obturator branch block is 
also effective to a reasonable extent in reducing 
spasticity. The selective block can be easily performed 
under ultrasound guidance as the nerve can be easily 
blocked under the 
ultrasound guidance. The duration of effect after ONB 
was followed up to 24 weeks in 82.6 % cases in our 
study. However, it varies from 2 months to 2 years in 
different studies, with the longest effect seen up to 36 
months irrespective of underlying disorder 7, 9. 
The widespread use of phenol as a neurolytic agent has 
largely been disregarded due to certain side effects like 
dysesthesia. But we have not found dysesthesia in any 
patient in our study. Previous studies on obturator nerve 
block for the treatment of hip adductor spasticity in 
adult patients reported that the complications were 
minimal, and pain and dysesthesia were not a problem 
even in patients with intact sensation10. Another study 
conducted by Ploypetch et al. using single event 
multilevel chemoneurolysis with combined BoNT-A and 
phenol didn’t show dysesthesia in 146 procedures 
performed in patients with cerebral palsy11. According 
to a retrospective study conducted by Karri et al. the 
commonly reported adverse events after phenol 
neurolysis in upper and lower extremity nerves were 
pain in 4.10%, inflammation 2.73%, hypotension and 
dysesthesia in 0.68% only12. 
When treatment of adductor spasticity with oral 
medicines, physiotherapy, splinting and stretching is 
not sufficiently effective in reducing spasticity, then 
obturator neurolysis with aqueous phenol may be tried. 
In the era of BoNT-A, the role of phenol could be seen 
as adjunctive therapy or an added tool in the 
management of focal or multifocal spasticity13. A smart 
benefit-risk analysis may help to target large proximal 
muscles being supplied by easily accessible, 
predominantly motor nerves with phenol neurolysis and 
distal small muscles with botulinum toxin. The main 
clinical scenarios where we can use phenol is sensitivity 
or previous adverse reaction/ unsuccessful treatment 
with BoNT-A injections or when the total dose of 
BoNT-A injection exceeds the recommended dosage13. 
Phenol can also be used if a longer duration of action is 
sought with high efficacy or if we want to cut down the 
cost of the procedure, especially in developing and 
underdeveloped countries. We recommend using the 
obturator neurolysis with phenol as a first-line 
procedure in patients who are not mobile, not able to 
attend the clinic every 4-months and unable to afford 
BoNT-A in healthcare systems where the patients have 
to pay the cost of their treatment. 
Various nerve localization techniques are used to guide 
the needle for this particular block, Electric stimulation 
(E-Stim) and ultrasound guidance are most commonly 
used. Accurate needle placement is the key to 
determine whether the block would be effective or 
otherswise. We used E-Stim of the target obturator 
nerve, which helped in precise localization of the nerve 
and dose adjustment7. Nowadays with advancement 
and the new trend of musculoskeletal ultrasound, more 
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and more nerve blocks are being performed under 
direct visualization, which can further increase the 
safety profile of this procedure and allow real-time 
visualization of the spread of solution8,14. A similar study 
reported by Akkaya and colleagues in 2010 reported 
90 obturator nerve blocks in 62 patients15. The primary 
outcome reported were pain, spasticity and hygiene at 
first week, first, second- and third-month 
post-injection. Pain was significantly decreased in first 
week, first month and second month’s follow-up. The 
Ashworth Scale improved in the second and third 
month. The hygiene score decreased drastically in the 
first week and the first and second months but 
worsened in the third month. The duration of action in 
this study was significantly less than in our study. 
Ofluoglu et al. in 2003 published their findings of 
phenol obturator nerve block in mobile patients with 
adducted gait pattern. They utilized temporospatial gait 
parameters and found that there was improvement in 
the width of the base of support without immediate 
change in velocity or step length16. In our clinical 
practice, we do not inject obturator nerve with phenol 
directly if the patients are mobile or are able to manage 
independent transfers. We proceed with a trial local 
anaesthetic obturator nerve block first, followed by the 
phenol nerve block to avoid any deterioration in walking 
and/or transfer ability. The trial anaesthetic nerve block 
has also been described in posterior tibial nerve block 
for ankle plantarflexor spasticity17. 
Further studies are needed to explore the effects of 
obturator nerve phenol block in mobile patients with 
severe adductor spasticity, to compare long term 
benefits after phenol versus BoNT-A injections and to 
see the prevalence of dysesthesia after this procedure, 
which is the main reason of phenol neurolysis to be less 
popular. It is also important to know the exact dosage 
of the phenol capable of producing the desired 
anti-spasticity effects by minimising the side-effects. 
The technique of obturator nerve block by using the 
nerve stimulator can be learned easily by experienced 
physicians with appropriate training. The rehabilitation 
physicians who have skills to use ultrasound scan can 
also learn to inject the anterior and posterior branches 
of the obturator nerve individually with the ultrasound. 
However, in severe spasticity where access to the groin 
is difficult due to the scissoring of the hip, both 
ultrasound and electric nerve stimulation can be 
technically difficult. In such circumstances, a landmark 
technique can be utilized to inject phenol to the 
obturator nerve18 without significant complications. 
Further research is needed to explore the long-term 
benefits, duration of effect and side-effect profile of 
phenol while managing spasticity.
CONCLUSION: 
Obturator nerve block with phenol is effective in 
reducing hip adductor spasticity with minimal 
side-effects. It is cost effective and reduces frequent 
clinic visits not only suitable for countries with 
struggling economy, but in rich/developed countries as 
an adjunct to BoNT-A. With appropriate training, the 
procedure is simple and easy to perform without major 
complications.
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